Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFLECT I: Fluorescence bronchoscopy with bevacizumab-800CW in suspected malignant pulmonary lesions
2024-510793-24-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in bronchial carcinoma, sponsored by University Medical Center Groningen. Primary endpoint: In vivo fluorescent signal comparison between malignant lesion and non-tumorous tissue. Planned start Jul 2026; status: authorised.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on 2024-510793-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510793-24-00.